ICUCW (SeaStar Medical Holding Corporation Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by ICUCW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-10 | Bradford K Towne | Principal Accounting Officer | A | — | — |
| 2026-02-10 | John Neuman | Director | A | — | — |
| 2026-02-10 | Kevin Chung | Chief Medical Officer | A | — | — |
| 2026-02-10 | Bernadette N Vincent | Director | A | — | — |
| 2026-02-10 | Eric Schlorff | Chief Executive Officer | A | — | — |
| 2026-02-10 | Kenneth Van Heel | Director | A | — | — |
| 2026-02-10 | Jennifer A Baird | Director | A | — | — |
| 2025-12-22 | Jennifer A Baird | Director | Buy | — | — |
| 2025-12-11 | Michael Messinger | Chief Financial Officer | Buy | — | — |
| 2025-08-28 | Kenneth Van Heel | Director | Buy | — | — |
| 2025-08-25 | Kevin Chung | Chief Medical Officer | Buy | — | — |
| 2025-07-16 | Bernadette N Vincent | Director | MIXED | — | — |
| 2025-07-16 | John Neuman | Director | MIXED | — | — |
| 2025-07-16 | Kenneth Van Heel | Director | MIXED | — | — |
| 2025-07-16 | Jennifer A Baird | Director | A | — | — |
| 2025-07-03 | Kevin Chung | Chief Medical Officer | M | — | — |
| 2025-07-03 | Eric Schlorff | Chief Executive Officer | M | — | — |
| 2025-07-02 | Jennifer A Baird | Director | MIXED | — | — |
| 2025-06-27 | John Neuman | Director | Buy | — | — |
| 2025-05-22 | Jennifer A Baird | Director | Buy | — | — |
| 2025-05-20 | Kevin Chung | Chief Medical Officer | Buy | — | — |
| 2025-04-03 | Kevin Chung | Chief Medical Officer | A | — | — |
| 2025-04-03 | David A Green | Chief Financial Officer | A | — | — |
| 2025-02-27 | John Neuman | Director | Buy | — | — |
| 2024-12-03 | Bernadette N Vincent | Director | A | — | — |
| 2024-12-03 | Jennifer A Baird | Director | A | — | — |
| 2024-11-19 | Kevin Chung | Chief Medical Officer | Buy | — | — |
| 2024-11-19 | Eric Schlorff | Chief Executive Officer | A | — | — |
| 2024-11-15 | Kenneth Van Heel | Director | A | — | — |
| 2024-11-15 | Rick Barnett | Director | A | — | — |
| 2024-11-15 | Allan Collins | Director | A | — | — |
| 2024-11-15 | John Neuman | Director | A | — | — |
| 2024-10-01 | Kevin Chung | Chief Medical Officer | Buy | — | — |
| 2024-09-09 | David A Green | Chief Financial Officer | A | — | — |
| 2024-09-09 | David A Green | Chief Financial Officer | A | — | — |
| 2024-04-16 | Allan Collins | Director | A | — | — |
| 2024-04-16 | Bruce M. Rodgers | Director | A | — | — |
| 2024-04-16 | Richard D. Russell | Director | A | — | — |
| 2024-04-16 | Kenneth Van Heel | Director | A | — | — |
| 2024-04-16 | Andres Lobo | Director | A | — | — |
| 2024-04-16 | David A Green | Chief Financial Officer | A | — | — |
| 2024-04-16 | Rick Barnett | Director | A | — | — |
| 2023-11-29 | Kevin Chung | Chief Medical Officer | A | — | — |
| 2023-11-29 | Eric Schlorff | Chief Executive Officer | A | — | — |
| 2023-11-29 | Caryl Baron | Interim CFO | MIXED | — | — |
| 2023-11-28 | Eric Schlorff | Chief Executive Officer | A | — | — |
| 2023-11-28 | Kevin Chung | Chief Medical Officer | A | — | — |
| 2023-11-28 | Eric Schlorff | Chief Executive Officer | A | — | — |
| 2023-11-27 | Kenneth Van Heel | Director | Buy | — | — |
| 2023-09-19 | Caryl Baron | Interim CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Interim CFO | 119,579 | — |
| — | Director | 86,664 | — |
| — | Director | 60,300 | — |
| — | Director | 54,343 | — |
| — | Director | 44,515 | — |
| — | Director | 40,300 | — |
| — | Chief Executive Officer | 39,852 | — |
| — | Chief Medical Officer | 20,819 | — |
| — | Chief Financial Officer | 17,500 | — |
| — | Director | 12,200 | — |
| — | Principal Accounting Officer | 9,050 | — |
| — | Director | 7,940 | — |
| — | Director | 6,620 | — |
| — | Director | 4,200 | — |
| — | Chief Financial Officer | 2,223 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ICUCW quote page; the site-wide leaderboard is on the insider transactions hub.